Alvimopan in the setting of colorectal resection with an ostomy: To use or not to use?

Surg Endosc. 2017 Sep;31(9):3483-3488. doi: 10.1007/s00464-016-5373-0. Epub 2016 Dec 7.

Abstract

Background: Postoperative ileus (POI) is a major cause of morbidity, increased length of stay (LOS) and hospital cost after colorectal surgery. Alvimopan is a µ-opioid antagonist used to accelerate upper and lower gastrointestinal function after bowel resection. We hypothesized that alvimopan would reduce LOS in patients undergoing colorectal resection with stoma, a situation that has not been evaluated.

Methods: A retrospective review (2010-2015) identified 58 patients who underwent colorectal resection for benign or malignant disease with stoma creation and received alvimopan. They were case-matched to 58 non-alvimopan patients based on age, BMI, baseline comorbidities, stoma type created and surgical approach. We compared overall LOS, incidence of POI and other postoperative complications.

Results: There were equal numbers of laparoscopic (N = 18) and open resections (N = 40) in the alvimopan group and non-alvimopan group. There were also equal numbers of patients with an ileostomy (N = 37) or colostomy (N = 21) in each group. Overall, 41 patients underwent resection for malignant disease in the alvimopan group compared to 37 in the non-alvimopan group. There was a significant reduction in median LOS overall (alvimopan 5 (4-7) versus control 6 (4.75-9.25) days, P = 0.03). While the 6-day median LOS was similar for patients undergoing ileostomy creation (P = 0.25), alvimopan patients had a 3-day decreased median LOS that approached statistical significance (P = 0.06). The overall 30-day complication rate was higher in the control group (41.4 vs. 51.7%, P = 0.26), but the readmission rate within 30 days was higher in the alvimopan group (19 vs. 13.8%, P = 0.45). Neither of these differences reached statistically significance.

Conclusion: The use of alvimopan in patients undergoing colorectal resection with stoma is associated with a significantly shorter LOS, but the increased readmission rate warrants further study. Based on these data, alvimopan should be evaluated in a controlled setting for patients undergoing colorectal resection with colostomy creation.

Keywords: Colorectal surgery; Enhanced recovery pathway; Ostomy.

MeSH terms

  • Adult
  • Aged
  • Colectomy*
  • Colonic Diseases / surgery
  • Female
  • Gastrointestinal Agents / therapeutic use*
  • Humans
  • Ileus / epidemiology
  • Ileus / etiology
  • Ileus / prevention & control*
  • Length of Stay / statistics & numerical data
  • Male
  • Middle Aged
  • Ostomy*
  • Piperidines / therapeutic use*
  • Postoperative Complications / epidemiology
  • Postoperative Complications / prevention & control*
  • Rectal Diseases / surgery
  • Rectum / surgery*
  • Retrospective Studies
  • Treatment Outcome

Substances

  • Gastrointestinal Agents
  • Piperidines
  • alvimopan